ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $3.19, but opened at $3.03. ImmunityBio shares last traded at $3.07, with a volume of 1,865,307 shares changing hands.
Analysts Set New Price Targets
A number of analysts recently issued reports on the company. Piper Sandler raised ImmunityBio from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $4.25 to $5.00 in a research report on Tuesday, May 20th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a research report on Wednesday, June 4th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Tuesday, June 3rd. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $12.25.
Read Our Latest Research Report on IBRX
ImmunityBio Price Performance
The business has a 50-day moving average of $2.63 and a 200-day moving average of $2.98. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of -3.34 and a beta of 0.14.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03). The business had revenue of $16.52 million during the quarter, compared to analysts' expectations of $17.50 million. As a group, equities analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.
Hedge Funds Weigh In On ImmunityBio
Institutional investors have recently bought and sold shares of the business. Slow Capital Inc. acquired a new position in ImmunityBio during the first quarter worth approximately $30,000. Compound Planning Inc. acquired a new position in ImmunityBio during the first quarter worth approximately $30,000. Thrive Wealth Management LLC acquired a new position in ImmunityBio during the first quarter worth approximately $30,000. Stephens Inc. AR bought a new stake in shares of ImmunityBio during the fourth quarter worth approximately $26,000. Finally, Xponance Inc. bought a new stake in shares of ImmunityBio during the first quarter worth approximately $33,000. Institutional investors and hedge funds own 8.58% of the company's stock.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
